Recent update on XBB.1.5 emerging novel mutation of COVID-19

被引：1
|
作者：
Amin, Ruhul [1 ]
Pal, Prosanta [2 ]
Dhama, Kuldeep [3 ]
Emran, Talha B. [4 ,5 ,6 ]
机构：
[1] Assam Down Town Univ, Fac Pharmaceut Sci, Gauhati, Assam, India
[2] Univ North Bengal, Dept Pharmaceut Technol, Darjeeling, West Bengal, India
[3] ICAR Indian Vet Res Inst, Div Pathol, Bareilly, Uttar Pradesh, India
[4] BGC Trust Univ Bangladesh, Dept Pharm, Chittagong, Bangladesh
[5] Daffodil Int Univ, Fac Allied Hlth Sci, Dept Pharm, Dhaka, Bangladesh
[6] BGC Trust Univ Bangladesh, Dept Pharm, Chittagong 4381, Bangladesh
来源：
INTERNATIONAL JOURNAL OF SURGERY | 2023年 / 109卷 / 04期
关键词：
D O I：
10.1097/JS9.0000000000000254
中图分类号：
R61 [外科手术学];
学科分类号：
摘要：
[No abstract available]
引用
收藏
页码：1048 / 1049
页数：2
相关论文
共 50 条
  • [41] GINCM-DTA: A graph isomorphic network with protein contact map representation for potential use against COVID-19 and Omicron subvariants BQ.1, BQ.1.1, XBB.1.5, XBB.1.16
    Chen, Guanxing
    He, Haohuai
    Zhao, Lu
    Lv, Qiujie
    Chen, Calvin Yu-Chian
    EXPERT SYSTEMS WITH APPLICATIONS, 2024, 236
  • [42] New variants of COVID-19 (XBB.1.5 and XBB.1.16, the "Arcturus"): A review of highly questioned concerns, a brief comparison between different peaks in the COVID-19 pandemic, with a focused systematic review on expert recommendations for prevention, vaccination, and treatment measures in the general population and at-risk groups
    Pourriyahi, Homa
    Hajizadeh, Nima
    Khosravi, Mina
    Pourriahi, Homayoun
    Soleimani, Sanaz
    Hosseini, Nastaran Sadat
    Mohammad, Arash Pour
    Goodarzi, Azadeh
    IMMUNITY INFLAMMATION AND DISEASE, 2024, 12 (06)
  • [43] Systemic and mucosal immune responses against the SARS-CoV-2 XBB.1.5, EG.5.1, and BA.2.86 lineages induced by monovalent XBB.1.5-adapted COVID-19 mRNA vaccines in patients with inflammatory bowel disease
    Woelfel, Simon
    Dueschlerl, Joel
    Junker, Daniel
    Konig, Marius
    Leinenkugel, Georg
    Graf, Nicole
    Krieger, Claudia
    Truniger, Samuel
    Franke, Annett
    Koller, Seraina
    Metzger-Peter, Katline
    Oberholzer, Melanie
    Frei, Nicola
    Geissler, Nora
    Schaub, Peter
    Albrich, Werner C.
    Friedrich, Matthias
    Niess, Jan Hendrik
    Schneiderhan-Marra, Nicole
    Dulovic, Alex
    Korte, Wolfgang
    Burgi, Justus J.
    Brand, Stephan
    SWISS MEDICAL WEEKLY, 2024, 154 : 11S - 11S
  • [44] Early COVID-19 XBB.1.5 Vaccine Effectiveness Against Hospitalisation Among Adults Targeted for Vaccination, VEBIS Hospital Network, Europe, October 2023-January 2024
    Antunes, Liliana
    Mazagatos, Clara
    Martinez-Baz, Ivan
    Naesens, Reinout
    Borg, Maria-Louise
    Petrovic, Goranka
    Fatukasi, Terra
    Jancoriene, Ligita
    Machado, Ausenda
    Oroszi, Beatrix
    Husa, Petr
    Lazar, Mihaela
    Duerrwald, Ralf
    Howard, Jennifer
    Melo, Aryse
    Perez-Gimeno, Gloria
    Castilla, Jesus
    Bernaert, Eva
    Dziugyte, Ausra
    Makaric, Zvjezdana Lovric
    Fitzgerald, Margaret
    Mickiene, Aukse
    Gomez, Veronica
    Turi, Gergo
    Souckova, Lenka
    Marin, Alexandru
    Tolksdorf, Kristin
    Nicolay, Nathalie
    Rose, Angela M. C.
    INFLUENZA AND OTHER RESPIRATORY VIRUSES, 2024, 18 (08)
  • [45] Active Surveillance for Safety Monitoring of XBB.1.5-Containing COVID-19 mRNA Vaccines in Korea
    Park, Bomi
    Lee, Hye Ah
    Kim, Yeonjae
    Kim, Chung Ho
    Park, Hyunjin
    Jun, Seunghee
    Lee, Hyelim
    Kwon, Seunghyun Lewis
    Heo, Yesul
    Lee, Hyungmin
    Park, Hyesook
    JOURNAL OF KOREAN MEDICAL SCIENCE, 2024, 39 (43)
  • [46] Real-world evaluation of early remdesivir in high-risk COVID-19 outpatients during Omicron including BQ.1/BQ.1.1/XBB.1.5
    Molina, Kyle C.
    Webb, Brandon J.
    Kennerley, Victoria
    Beaty, Laurel E.
    Bennett, Tellen D.
    Carlson, Nichole E.
    Mayer, David A.
    Peers, Jennifer L.
    Russell, Seth
    Wynia, Matthew K.
    Aggarwal, Neil R.
    Ginde, Adit A.
    BMC INFECTIOUS DISEASES, 2024, 24 (01)
  • [47] STAR SIGN study: Evaluation of COVID-19 vaccine efficacy against the SARS-CoV-2 variants BQ.1.1 and XBB.1.5 in patients with inflammatory bowel disease
    Woelfel, Simon
    Duetschler, Joel
    Koenig, Marius
    Dulovic, Alex
    Graf, Nicole
    Junker, Daniel
    Oikonomou, Vasileios
    Krieger, Claudia
    Truniger, Samuel
    Franke, Annett
    Eckhold, Annika
    Forsch, Kristina
    Koller, Seraina
    Wyss, Jacqueline
    Krupka, Niklas
    Oberholzer, Melanie
    Frei, Nicola
    Geissler, Nora
    Schaub, Peter C.
    STAR SIGN Study Investigator, Matthias
    Albrich, Werner
    Friedrich, Matthias
    Schneiderhan-Marra, Nicole
    Misselwitz, Benjamin J.
    Korte, Wolfgang
    Buergi, Justus
    Brand, Stephan
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2023, 58 (07) : 678 - 691
  • [48] A recent update of anticoagulant therapy on severe COVID-19 patients
    Rusdiana, Taofik
    Putriana, Norisca Aliza
    Husni, Patihul
    Akbar, Mohammad Rizki
    Araki, Takuya
    Subarnas, Anas
    JOURNAL OF RESEARCH IN PHARMACY, 2021, 25 (06): : 807 - 814
  • [49] Update on Bimervax® immunogenicity amplitude. Insights on humoral response against XBB.1.5 from an extension study (NTC05142553)
    Borralleras, Cristina
    Castrodeza Sanz, Javier
    Arrazola, Pilar
    Camara-Hijon, Carmen
    Maria Eiros, Jose
    Fernandez Prada, Maria
    Gil de Miguel, Angel
    Mirada, Gloria
    Moraga-Llop, Fernando
    Ocana Rodriguez, Daniel
    Puig-Barbera, Joan
    Vazquez, Jorge
    Vergara-Alert, Julia
    de Cambra, Salome
    REVISTA ESPANOLA DE QUIMIOTERAPIA, 2023, 36 (06) : 658 - 660
  • [50] COVID-19 UPDATE
    Haberal, Mehmet
    EXPERIMENTAL AND CLINICAL TRANSPLANTATION, 2020, 18 (02) : 139 - 139
12345